<DOC>
	<DOCNO>NCT02402712</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter , Phase IIIb study evaluate safety tolerability Herceptin SC combination Perjeta IV plus docetaxel female patient HER2-positive metastatic locally recurrent breast cancer . Enrolled patient receive study medication disease progression , unacceptable toxicity , withdrawal consent , death , predefined study end , whichever occur first . The anticipated time study treatment approximately 24 month . The target sample size 400 .</brief_summary>
	<brief_title>Phase IIIb Study Evaluate Safety Tolerability Herceptin SC With Perjeta Docetaxel Patients With HER2-positive Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm documented adenocarcinoma breast metastatic locally recurrent disease amenable curative resection . Patients measurable and/or nonmeasurable disease evaluable accord Response Evaluation Criteria Solid Tumors ( RECIST ) , Version 1.1 eligible . HER2positive disease ( define either immunohistochemistry [ IHC ] 3 + situ hybridization [ ISH ] positive ) assess local laboratory primary tumor metastatic site primary tumor available Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Left ventricular ejection fraction ( LVEF ) least 50 % Negative serum pregnancy test result baseline use effective contraception define protocol Previous systemic nonhormonal anticancer therapy metastatic locally recurrent disease . Note : Prior study entry , two line hormonal therapy metastatic locally recurrent disease permit , one may combination everolimus . Diseasefree interval le 6 month completion adjuvant neoadjuvant systemic nonhormonal treatment recurrence breast cancer Previous approve investigative antiHER2 agent neoadjuvant adjuvant therapy breast cancer treatment , except Herceptin History persistent Grade 2 high hematological toxicity result previous adjuvant neoadjuvant therapy Radiographic evidence central nervous system ( CNS ) metastases assess computed tomography ( CT ) magnetic resonance imaging ( MRI ) , unless treat stable least 3 month require ongoing corticosteroid treatment Current peripheral neuropathy Grade 3 great History malignancy within last 5 year prior first dose study drug administration , except carcinoma situ cervix basal cell carcinoma Inadequate organ function Uncontrolled hypertension without medication Clinically significant cardiovascular disease History LVEF decline 50 % prior Herceptin neoadjuvant adjuvant therapy Current know infection HIV , hepatitis B virus , hepatitis C virus Severe uncontrolled concomitant disease would contraindicate use investigational drug use study would put patient high risk treatmentrelated complication , include severe pulmonary conditions/illness Pregnant lactate woman Dyspnea rest due complication advance malignancy disease require continuous oxygen therapy History receive investigational treatment within 28 day prior first dose study drug administration ( dose ) concurrent participation interventional clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>